Compounds > 2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha
Page last updated: 2024-09-04

2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha and thromboxanes

2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha has been researched along with thromboxanes in 1 studies

Compound Research Comparison

Studies
(2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha)		Trials
(2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha)		Recent Studies (post-2010)
(2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha)		Studies
(thromboxanes)		Trials
(thromboxanes)		Recent Studies (post-2010) (thromboxanes)
6103,202149199

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brash, AR; FitzGerald, GA; Lawson, JA; Maas, RL; Oates, JA; Roberts, LJ1

Other Studies

1 other study(ies) available for 2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha and thromboxanes

ArticleYear
Aspirin inhibits endogenous prostacyclin and thromboxane biosynthesis in man.
    Advances in prostaglandin, thromboxane, and leukotriene research, 1983, Volume: 11

    Topics: Aspirin; Humans; Kinetics; Prostaglandins F, Synthetic; Thromboxane B2; Thromboxanes

1983